



NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

Date: January 15, 2010

To: Primary Clinical Research Associates

From: Sara Braun
Research Protocol Specialist III

Re: N057K, Phase I/II Evaluation of Everolimus (RAD001), Radiation and Temozolomide (TMZ) Followed by Adjuvant Temozolomide and Everolimus in Newly Diagnosed Glioblastoma

The “Pre-Registration Eligibility Checklist” has been revised as follows.

Form Title	Brief Description of Edit
Pre-Registration Eligibility Checklist	Added to the bottom of page 1: <ul style="list-style-type: none">• Is your site using IMRT for this study?

If you have any questions, please feel free to contact me.

Enclosure